(LPTH) Announces The Exercise Of Warrants

Cash Balance Projected to Nearly Double

ORLANDO, Fla., Aug. 7, 2013 /PRNewswire/ — LightPath Technologies, Inc. (NASDAQ: LPTH) (the “Company”, “LightPath” or “we”), a global manufacturer, distributor and integrator of proprietary optical components and assemblies, today announced that 776,418 warrants which were previously issued were committed for exercise into common shares during the months of July and August of 2013.  The Company received aggregate gross proceeds from these exercises to total approximately $1.22 million.

As previously disclosed, cash on hand as of June 30, 2013 was approximately $1.57 million, which was an increase of 12% as compared to approximately $1.40 million on March 31, 2013.  The aggregate proceeds from the warrant conversions have increased the Company’s cash position to greater than $3.00 million.

Following the exercise of the aforementioned warrants, the Company’s issued and outstanding ordinary share count will be approximately 13.74 million ordinary shares.  Four members of the Company’s management team and Board of Directors exercised warrants into common shares increasing their ownership percentage.

“The exercising of warrants demonstrates the confidence shareholders, particularly our management team and members of our Board of Directors, have in our growth prospects, as well as serve to significantly strengthen our balance sheet.  We are grateful for this continued support and look confidently toward the future,” said Jim Gaynor, President and Chief Executive Officer of LightPath.

LightPath has an additional 2.55 million warrants at a weighted average exercise price of $1.43 (exercise prices ranging between $0.87-$3.20) relating to capital transactions since fiscal 2009. The warrants have expiration dates through December 2017.

About LightPath Technologies

LightPath (NASDAQ: LPTH) manufactures optical products including precision molded aspheric optics, GRADIUM® glass products, proprietary collimator assemblies, laser components utilizing proprietary automation technology, higher-level assemblies and packing solutions. The Company’s products are used in various markets, including industrial, medical, defense, test & measurement and telecommunications. LightPath has a strong patent portfolio that has been granted or licensed to us in these fields.  For more information, visit www.lightpath.com.

This news release includes statements that constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This information may involve risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, factors detailed by LightPath Technologies, Inc. in its public filings with the Securities and Exchange Commission. Except as required under the federal securities laws and the rules and regulations of the Securities and Exchange Commission, the Company does not have any intention or obligation to update publicly any forward-looking statements whether as a result of new information, future events or otherwise.

GRADIUM^® is a registered trademark of LightPath Technologies.

(CSOD) CFO to Present at Pacific Crest Global Technology Leadership Forum

Cornerstone OnDemand (NASDAQ:CSOD), a global leader in cloud-based talent management software solutions, today announced that the company’s CFO, Perry Wallack, will present at the following investor conference:

• What: Pacific Crest Global Technology Leadership Forum
• When: Monday, August 12, 2013 at 3:00 p.m. MT
• Where: The Sonnenalp, Vail, Colo.

An audio webcast of the presentation will be available on Cornerstone’s investor relations Web site at investors.cornerstoneondemand.com.

About Cornerstone OnDemand

Cornerstone OnDemand is a leader in cloud-based applications for talent management. Our solutions help organizations recruit, train, manage and connect their employees, empowering their people and increasing workforce productivity. Based in Santa Monica, California, the company’s solutions are used by more than 1,400 companies worldwide, spanning over 12 million users across 190 countries and 41 languages. For more information about Cornerstone, visit www.csod.com. Read Cornerstone’s blog at www.csod.com/blog. Follow Cornerstone on Twitter at www.twitter.com/CornerstoneInc. Like us on Facebook at www.facebook.com/CSODcommunity.

Cornerstone® and Cornerstone OnDemand® are registered trademarks of Cornerstone OnDemand Inc.

(CXM) Excellagen Distribution Agreement With Kasiak For Germany, Switzerland

SAN DIEGO, Aug. 7, 2013 /PRNewswire/ — Cardium Therapeutics (NYSE MKT: CXM) today announced that it has entered into a distribution agreement with Kasiak Holdings AG for the marketing and sale of Excellagen^® advanced wound care product in Germany and Switzerland.  Kasiak Holdings is focused on developing stem cell-based therapeutics for the treatment of diabetic foot ulcers.  Kasiak Holdings is affiliated with Kasiak Research, which is an operating unit of India-based Bharat Serums and Vaccines, that develops and manufactures specialized biological, pharmaceutical and biotechnology products.

Cardium’s FDA-cleared Excellagen is an aseptically-manufactured, quaternary fibrillar Type I bovine collagen homogenate that is configured into a staggered array of three-dimensional, triple helical, telopeptide-deleted, tropocollagen molecules.  This linear array forms a flowable, biocompatible and bioactive structural matrix that can promote chemotaxis, cellular adhesion, migration and proliferation to stimulate tissue formation. The Excellagen homogenate represents a new product delivery platform that allows for the potential development of a portfolio of advanced tissue regeneration therapeutic opportunities that could include anti-infectives, antibiotics, peptides, proteins, small molecules, DNA, stem cells, differentiated cells and conditioned cell media.

About Excellagen
Excellagen is a syringe-based, professional-use, pharmaceutically-formulated 2.6% fibrillar Type I bovine collagen homogenate that functions as an acellular biological modulator to activate the wound healing process and significantly accelerate the growth of granulation tissue.  Excellagen’s FDA clearance provides for very broad labeling including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/graft, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds.  Excellagen is intended for professional use following standard debridement procedures in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors.  Excellagen’s unique fibrillar Type I bovine collagen homogenate formulation is topically applied through easy-to-control, pre-filled, sterile, single-use syringes and is designed for application at only one-week intervals.

There have been important, positive findings reported by physicians using Excellagen as part of Cardium’s physician sampling, patient outreach and market “seeding” programs.  In several case studies, physicians reported a rapid onset of the growth of granulation tissue in a wide array of wounds, including non-healing diabetic foot ulcers (consistent with the results of Cardium’s Matrix clinical study), as well as pressure ulcers, venous ulcers and Mohs surgical wounds.  In certain cases, rapid granulation tissue growth and wound closure have been achieved with Excellagen following unsuccessful treatment with other advanced wound care approaches.  From a dermatology perspective, a previously unexplored vertical market, remarkable healing responses have been observed following Mohs surgery for patients diagnosed with squamous and basal cell carcinomas, including deep surgical wounds extending to the periosteum (a membrane that lines the outer surface of bones).  Additionally, because of the easy-use and platelet activating capacity, physicians have been employing Excellagen in severe non-healing wounds at near-amputation status, in combination with autologous platelet-rich plasma therapy and collagen sheet products.  These case studies and positive physician feedback provide additional support of Excellagen’s potential utility as an important new tool to help promote the wound healing process.  Excellagen case studies are available at http://www.excellagen.com/surgical-wounds.html.

About Kasiak Holding AG
Kasiak Holding AG (KHAG), initiated as an Indo-German Joint Venture, is developing novel biologics for regenerative medicine including stem cell based therapies for diabetic foot ulcers. Kasiak has operations in Europe and India and is affiliated with Kasiak Research which is part of Bharat Serums and Vaccines (BSV) group of companies which develops and manufactures specialized biological, pharmaceutical and biotechnology products.  Additional information about Kasiak Research is available at http://kasiakresearch.com/home.html

About Cardium
Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium’s current portfolio includes LifeAgain medical data analytics, Tissue Repair Company, Cardium Biologics, and the Company’s To Go Brands^® nutraceutical business. The Company’s lead commercial product, Excellagen^® topical gel for wound care management, has received FDA clearance for marketing and sale in the United States.  Cardium’s lead clinical development product candidate Generx^® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. To Go Brands^® develops, markets and sells dietary supplements through established regional and national retailers.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. For more information, visit www.cardiumthx.com.

Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations.  For example, there can be no assurance that this or other distribution agreements will effectively expand access or lead to increased adoption by medical providers in Germany and Switzerland; that case study observations will be reproducible or generalizable, or that results or trends observed in a clinical study or follow-on case studies will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2013 Cardium Therapeutics, Inc.  All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics^®, Generx^®,Cardionovo^®, Tissue Repair™, Excellagen^®, Excellarate™, LifeAgain™, Genedexa™, Neo-Apps^®, MedPodium^®, Neo-Energy^®, Neo-Chill™ and Neo-Carb Bloc^® are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.  To Go Brands^®,  High Octane^®, Green Tea Energy Fusion™, Acai Natural Energy Boost™, Greens to Go^®, Extreme Berries to Go^®, Healthy Belly^®, VitaRocks^®, Smoothie Complete^®, Trim Green Coffee Bean™, and Trim Energy^®, are trademarks of To Go Brands, Inc.  Other trademarks belong to their respective owners.

(NBS) Appoints Douglas W. Losordo as Chief Medical Officer

Andrew L. Pecora to Assume New Role as Chief Visionary Officer

NEW YORK, Aug. 6, 2013 (GLOBE NEWSWIRE) — NeoStem, Inc. (Nasdaq:NBS) (“NeoStem” or the “Company”), a leader in the emerging cellular therapy market, announced today the appointment of Douglas W. Losordo, MD, FACC, FAHA, as Chief Medical Officer of the Company. Dr. Losordo is a leader in cell therapy research and a renowned cardiologist. Most recently, Dr. Losordo was Vice President, New Therapies Development, Regenerative Medicine and Baxter Ventures at Baxter International.

Dr. Losordo is well regarded for his career-long efforts to develop novel therapeutics and as a scientist he obtained over $35 million in National Institutes of Health funding for discovering and developing new therapeutic concepts in the laboratory, providing the basis for clinical studies. He has led first in human studies in multiple gene and adult stem cell therapies in patients with cardiovascular diseases, including therapies now in Phase 3 testing. He is a highly sought after speaker, having given over 200 international lectures. He is an associate editor of Circulation Research, the basic science journal of the American Heart Association and serves on the editorial boards of a number of scientific journals.

“I am excited to join NeoStem in its pursuit of promising cell therapies, including a product candidate using CD34+ cells to repair ischemic tissue, taking us a step closer to true disease modification or reversal, instead of relegating patients to symptom palliation,” said Dr. Losordo. “The Company is hard at work to unlock the future of cell therapies, a shared goal to which I have also devoted my professional career.”

Andrew L. Pecora, MD, FACC, the Company’s outgoing Chief Medical Officer, will assume the role of Chief Visionary Officer of NeoStem, where he will continue to assist in building a leading global cell therapy company. Dr. Pecora will also continue in his role as Chief Medical Officer of Progenitor Cell Therapy (“PCT”), NeoStem’s contract development and manufacturing subsidiary, and Chief Scientific Officer of Amorcyte, LLC, NeoStem’s subsidiary developing a cell therapy to preserve heart muscle function after a severe heart attack, as well as remain a member of NeoStem’s Board of Directors.

Dr. Andrew Pecora said, “The Company has made a sound investment in Dr. Losordo who is an extremely talented and well-respected physician researcher in the cell therapy field. I look forward to collaborating with Dr. Losordo as the Company continues to identify and evaluate regenerative medicine opportunities.”

Dr. Robin L. Smith, Chairman and CEO of NeoStem, said “We are extremely fortunate to have Doug Losordo join our leadership team. Doug will no doubt complement the stellar medical regime that Andrew Pecora has built, as well as help us move forward in our efforts to develop novel proprietary cell therapy products and platform technologies.”

Dr. Losordo is an adjunct professor of medicine at Northwestern University in Chicago, Illinois. From 2006 to 2011, he was the director of the Feinberg Cardiovascular Research Institute and the Eileen M. Foell Professor of Heart Research at Northwestern University’s School of Medicine and director of the Program in Cardiovascular Regenerative Medicine at Northwestern Memorial Hospital. From 2004 to 2006, he was a Professor of Medicine at Tufts University School of Medicine and Chief of Cardiovascular Research at St. Elizabeth’s Medical Center in Boston.  He is board-certified in internal medicine, cardiovascular disease, and interventional cardiology. Dr. Losordo’s major research interests encompass angiogenesis/vasculogenesis, progenitor/adult stem cells, tissue repair/regeneration, and vascular biology. He received his medical degree from the University of Vermont.

About NeoStem, Inc.

NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy product, as well as operating a contract development and manufacturing organization that provides services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

For more information, please visit: www.neostem.com

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, including with respect to the Company’s research and development and clinical evaluation efforts as well as efforts towards development of cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company’s ability to successfully grow its contract development and manufacturing business. The Company’s actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company’s periodic filings with the SEC. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: NeoStem
         Eric Powers
         Manager of Communications and Marketing
         Phone: +1-212-584-4173
         Email: epowers@neostem.com

(QLYS) Appoints Defense, Homeland Security Expert Kristi M. Rogers to Board

Rogers Brings Experience Providing Security Solutions to U.S. Federal Civilian, Defense and Intelligence Agencies, Foreign Governments and Private Sector Companies

Qualys Appoints Defense and Homeland Security Expert Kristi M. Rogers to Board of Directors

Rogers Brings Experience Providing Security Solutions to U.S. Federal Civilian, Defense and Intelligence Agencies, Foreign Governments and Private Sector Companies

REDWOOD CITY, CA–(Marketwired – Aug 6, 2013) – Qualys, Inc. (NASDAQ: QLYS), a pioneer and leading provider of cloud security and compliance solutions, today announced its appointment of Kristi M. Rogers to its Board of Directors. Rogers, currently the managing director of Federal Government Affairs and Public Policy for Manatt, Phelps & Phillips, LLP, will provide strategic guidance as Qualys continues to expand its cloud security and compliance solutions to meet the needs of global organizations in both the public and private sectors.

“The internet is global, and the world of security and defense is constantly changing. Qualys is in a unique position with its QualysGuard Cloud Platform to provide organizations worldwide with the acumen and agility to fend off threats,” said Rogers. “I am looking forward to serving on the Qualys Board of Directors to help as the company expands its much-needed services worldwide.”

“Kristi’s impressive background includes working with government and corporate clients from all over the world to deliver effective defense and security solutions,” said Philippe Courtot, chairman and CEO, Qualys. “Her keen understanding of their needs and of the challenges they face will help us better serve them as we expand our services and business to new areas.”

About Kristi M. Rogers
Currently the managing director of Federal Government Affairs and Public Policy for Manatt, Phelps & Phillips, Kristi M. Rogers has more than 20 years of experience in strategic business development, program management, corporate leadership, crisis communication and executive level problem solving in the defense and homeland security sectors, as well as senior executive service in the U.S. Government. Prior to joining Manatt, Rogers served in multiple senior leadership roles, including president, CEO and vice chair of the board of directors at Aegis Defense Services, LLC, a risk management and private security company. Before joining Aegis, Rogers was assistant commissioner of public affairs for U.S. Customs & Border Protection, and has served in Iraq as Ambassador L. Paul Bremer’s strategic communications liaison to his cabinet of senior advisors, and as the director of strategic communications in the press office of the Coalition Provisional Authority. She also held several senior positions within federal government offices, including Department of Transportation and Small Business Administration. Rogers has a bachelor’s degree in political science from Michigan State University.

About Qualys
Qualys, Inc. (NASDAQ: QLYS), is a pioneer and leading provider of cloud security and compliance solutions with over 6,000 customers in more than 100 countries, including a majority of each of the Forbes Global 100 and Fortune 100. The QualysGuard Cloud Platform and integrated suite of solutions help organizations simplify security operations and lower the cost of compliance by delivering critical security intelligence on demand and automating the full spectrum of auditing, compliance and protection for IT systems and web applications. Founded in 1999, Qualys has established strategic partnerships with leading managed service providers and consulting organizations, including Accuvant, BT, Dell SecureWorks, Fujitsu, NTT, Symantec, Verizon, and Wipro. The company is also a founding member of the Cloud Security Alliance (CSA).

For more information, please visit www.qualys.com.

Qualys, the Qualys logo and QualysGuard are proprietary trademarks of Qualys, Inc. All other products or names may be trademarks of their respective companies.

(SGOC) to Announce Financial Results for Second Quarter on Aug 20

BEIJING, Aug. 6, 2013 /PRNewswire/ — SGOCO Group, Ltd. (Nasdaq: SGOC), (“SGOCO” or the “Company”), a company focused on product design, distribution, and brand development in flat-panel display market, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2013 on Tuesday, August 20, 2013 after the U.S. market closes. The earnings press release will be available at http://www.sgocogroup.com.

Following the earnings announcement, SGOCO’s senior management will host a conference call on Wednesday, August 21, 2013 at 8 a.m. (Eastern) / 5 a.m. (Pacific) / 8 p.m. (Beijing / Hong Kong) to discuss quarterly results and operational updates.

To access the conference call, please dial in at least 10 minutes before the call.

1-877-941-4774 (US Toll-free)
1-480-629-9760 (International)
4001-200-611 (China Toll-free)
86-400-628-0671 (China)

Conference call identification number: 4632020

The Company will also broadcast a live audio webcast of the conference call. The webcast will be available at http://public.viavid.com/index.php?id=105494

An archive of the call will be available within 48 hours at http://www.sgocogroup.com/us/SGOC/irwebsite/index.php?mod=recent&id=16

About SGOCO Group, Ltd.

SGOCO Group, Ltd. is a company focused on product design, brand development, and distribution in flat-panel display market, including computer monitors, TVs, and application specific products. The Company sells its products and services in the Chinese market and abroad. For more information about SGOCO, please visit our investor relations website http://www.sgocogroup.com.

For investor and media inquiries, please contact:

SGOCO Group, Ltd.

Serena Wu
Investor Relations Manager
Tel: +86-10-8587-0170 ext 815 (China)
US: 1-(646) 583-1616 (voice mail)
Email: ir@sgoco.com

Safe Harbor and Informational Statement

This announcement contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of the Company set forth herein and those preceded by or that include the words “believe,” “expect,” “anticipate,” “future,” “will,” “intend,” “plan,” “estimate” or similar expressions, are “forward-looking statements”. Forward-looking statements in this release include, without limitation, the effectiveness of the Company’s multiple-brand, multiple channel strategy and the transitioning of its product development and sales focus and to a “light-asset” model, Although the Company’s management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated. These forward-looking statements can change as a result of many possible events or factors not all of which are known to the Company, which may include, without limitation, requirements or changes adversely affecting the LCD and LED market in China; fluctuations in customer demand for LCD and LED products generally; our success in promoting our brand of LCD and LED products in China and elsewhere; our ability to have effective internal control over financial reporting; our success in designing and distributing products under brands licensed from others; management of sales trend and client mix; possibility of securing loans and other financing without efficient fixed assets as collaterals; changes in government policy in China; the fluctuations and competition in sales and sale prices of LCD and LED products in China; China’s overall economic conditions and local market economic conditions; our ability to expand through strategic acquisitions and establishment of new locations; changing principles of generally accepted accounting principles; compliance with government regulations; legislation or regulatory environments; geopolitical events, and other events and/or risks outlined in SGOCO’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F and other filings. All information provided in this press release and in the attachments is as of the date of the issuance, and SGOCO does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

(NEWT) Reports 67% Increase In Second Quarter Diluted EPS

Second Quarter 2013 Total Operating Revenues Up 14.5% to $37 Million Company Reaffirms 2013 Guidance; Expects 20% Growth in Diluted Earnings Per Share in 2013

NEW YORK, Aug. 6, 2013 /PRNewswire/ — Newtek Business Services, Inc. (NASDAQ: NEWT) (www.thesba.com) The Small Business Authority^®, a provider of business services and financial products to the small- and medium-sized business market, reported today its financial results for the quarter ended June 30, 2013.

Second Quarter 2013 Consolidated Highlights:

• Diluted earnings per share (“EPS”) were $0.05; an increase of 66.7% over $0.03 in the second quarter of 2012.
• For the six months ended June 30, 2013, EPS were $0.09; an increase of 50.0% over $0.06 for the six months ended June 30, 2012.
• Consolidated pretax income was $2.9 million; an increase of 48.0% over $1.9 million in the second quarter of 2012.
• Net income attributable to Newtek Business Services, Inc. was $1.8 million; an increase of 48.2% over $1.2 million in the second quarter of 2012.
• Modified EBITDA was $5.2 million; an increase of 39.3% over $3.7 million in the second quarter of 2012.
• Operating revenues were $37.0 million; an increase of 14.5% over $32.3 million in the second quarter of 2012.

Second Quarter 2013 Operating Segment Highlights:

• Small business finance segment pretax income was $2.0 million; an increase of 37.3% over $1.5 million in the second quarter of 2012.
• The SBA lender funded $42.8 million in loans during the second quarter of 2013; an increase of 103.7% over $21.0 million in the second quarter of 2012.
• Electronic payment processing segment pretax income was $2.5 million; an increase of 28.4% over $1.9 million in the second quarter of 2012.

Reaffirmation of 2013 Consolidated Guidance:

• The Company expects:
  • EPS midpoint forecast at $0.18 per share, with a range of $0.17 and $0.19, which represents an increase of 20.0% over 2012 diluted EPS.
  • ­Revenue midpoint forecast at $148.2 million, with a range of $145.1 million and $151.2 million, which represents an increase of 13.0% over 2012 revenue.
  • ­Pretax income midpoint forecast at $11.5 million, with a range of $10.0 million and $13.0 million, which represents an increase of 22.3% over 2012 pretax income.
  • ­Modified EBITDA midpoint forecast at $20.9 million, with a range of $19.3 million and $22.4 million, which represents an increase of 25.4% over 2012 Modified EBITDA.
• The Company expects to fund between $160 million and $190 million of SBA 7(a) loans in 2013.
• The Company expects to increase its total loan servicing portfolio by a minimum of 32.4% to at least $700 million by the end of 2013.

Barry Sloane, Chairman, President and Chief Executive Officer said, “We are pleased with this quarter’s results, with a 67% increase in diluted earnings per share to $0.05.  That said, historically, the second half of the year has proven to be stronger than the first half of the year.  Having reached earnings of $0.09 per share for the first six months of this year, we believe we are well-poised to deliver at least 20% growth in earnings for 2013.

“Our three primary segments – Small business finance, Electronic payment processing and Managed technology solutions – all made solid contributions to our overall results for the quarter.”  Mr. Sloane explained, “We continue to be the largest non-bank SBA 7(a) lender and the 11^th largest government-guaranteed SBA 7(a) lender in the U.S. including banks.  Our funded loan amount increased by over 100% to $42.8 million in the second quarter, bringing total funded loans to almost $80 million for the first six months of the year.  With our current robust lending pipeline of $391 million, we expect to grow our funded loans by approximately 63% to $175 million in 2013, and expect continued loan growth in 2014 and beyond.

“Furthermore, we experienced an increase of nearly 30% in pretax income and approximately 10% revenue growth in our Electronic payment processing segment. We increased our average monthly processing volume per merchant by 8% year over year, and currently anticipate processing approximately $4.5 billion of annualized electronic payment processing volume by the end of 2013.  Going forward, if we can increase our client base through our independent sales organization (ISO) channel, our Electronic payment processing segment should realize a significant increase in revenue during the second half of 2013.

“Finally, we are pleased to report that we have begun to reap the benefits of our repositioning strategy in our Managed technology solutions segment, evidenced by this quarter’s reversal to a slight year-over-year increase in revenue in this segment as well as the sequential upward trend in both revenue and pretax income over the first quarter of 2013.  Our upgrade to Linux-based platforms and the increase in our cloud-based offerings have fostered the growth in this segment, and we believe will enable us to capture additional market share in this space.  Notably, we continued to achieve year-over-year growth in key metrics including a 187% increase in new Linux accounts within our cloud environment.  Cloud-computing instances and cloud service accounts increased by 8% and 31%, respectively, further illustrating the growth in our cloud-based offerings.  As our strategy continues to take a greater hold, we fully expect to maintain this upward trend, and expect a year-over-year increase in revenue of approximately 3% in 2013.”

Mr. Sloane concluded, “The Small Business Authority^® brand continues to provide high levels of satisfaction to independent business owners in all 50 states.  Evidenced by our consistent top- and bottom-line growth, Newtek is quickly becoming the brand of choice for small- and medium-sized businesses with our myriad of financial and technological solutions coupled with our premier level of service.  And while we have experienced significant growth both financially and operationally, we still have a tremendous opportunity to continue to penetrate the vast small- to medium-sized business market of over 27.5 million businesses.  In short, we believe the best is yet to come, and we anticipate delivering our fourth consecutive year of growth and upward trending profitability in 2013, with guidance of a 13% increase in operating revenues and a 22% increase in pretax net income.”

Cautionary Statement

2013 Guidance information contained in this press release is based on management’s current expectations.  These statements are forward-looking and actual results may differ materially.  See “Note Regarding Forward-Looking Statements” below.

Use of Non-GAAP Financial Measures

In evaluating its business, Newtek considers and uses Modified EBITDA as a supplemental measure of its operating performance.  The Company defines Modified EBITDA as earnings before income from tax credits, interest expense, taxes, depreciation and amortization, stock compensation expense, other than temporary decline in value of investments, Capco fair value change and the amortization of the 2011 accrued loss on the lease restructure.  The Company also presents Modified EBITDA because it believes it is frequently used by securities analysts, investors and other interested parties as a measure of financial performance.

The term Modified EBITDA is not defined under U.S. generally accepted accounting principles, or U.S. GAAP, and is not a measure of operating income (loss), operating performance or liquidity presented in accordance with U.S. GAAP.  Modified EBITDA has limitations as an analytical tool and, when assessing the Company’s operating performance, investors should not consider Modified EBITDA in isolation, or as a substitute for net income (loss) or other consolidated income statement data prepared in accordance with U.S. GAAP.  Among other things, Modified EBITDA does not reflect the Company’s actual cash expenditures.  Other companies may calculate similar measures differently than Newtek, limiting their usefulness as comparative tools.  The Company compensates for these limitations by relying primarily on its GAAP results supplemented by Modified EBITDA.

Investor Conference Call and Webcast

A conference call to discuss second quarter 2013 results will be hosted by Barry Sloane, Chairman, President and Chief Executive Officer, and Jennifer Eddelson, Executive Vice President and Chief Accounting Officer, today, Tuesday, August 6, 2013 at 4:15 p.m. EDT.  The live conference call can be accessed by dialing (877) 303-6993 or (760) 666-3611.

A live audio webcast of the call and the corresponding presentation will be available in the ‘Events & Presentation’ section of the Investor Relations portion of Newtek’s website at http://investor.newtekbusinessservices.com/events.cfm.  A replay of the webcast with the corresponding presentation will be available on Newtek’s website shortly following the live presentation.

About Newtek Business Services, Inc.

Newtek Business Services, Inc., The Small Business Authority^®, is a direct distributor of a wide range of business services and financial products to the small- and medium-sized business market under the Newtek^® brand. Since 1999, Newtek has helped small- and medium-sized business owners realize their potential by providing them with the essential tools needed to manage and grow their businesses and to compete effectively in today’s marketplace. Newtek provides one or more of its services to over 100,000 business accounts and has positioned the Newtek^® and The Small Business Authority brands as a one-stop-shop provider of such business services. According to the U.S. Small Business Administration, there are over 27.5 million small businesses in the United States, which in total represent 99.7% of all employer firms.

Newtek Business Services, The Small Business Authority^®, provides the following products and services:

• Electronic Payment Processing: eCommerce, electronic solutions to accept non-cash payments, including credit and debit cards, check conversion, remote deposit capture, ACH processing, and electronic gift and loyalty card programs.
• Business Lending: Broad array of lending products including SBA 7(a) and SBA 504 loans.
• Web Hosting:  Full-service web host which offers eCommerce solutions, shared and dedicated web hosting and related services including domain registration and online shopping cart tools.
• eCommerce:  A suite of services that enable small businesses to get up and running on-line quickly and cost effectively, with integrated web design, payment processing and shopping cart services.
• Web Services: Customized web design and development services.
• Data Backup, Storage and Retrieval: Fast, secure, off-site data backup, storage and retrieval designed to meet the specific regulatory and compliance needs of any business.
• Insurance Services: Commercial and personal lines of insurance, including health and employee benefits in all 50 states, working with over 40 insurance carriers.
• Accounts Receivable Financing: Receivable purchasing and financing services.
• Payroll: Complete payroll management and processing services.
• The Newtek Advantage™: A mobile real-time SMB management platform that puts all of a business’s critical transactions and economic, eCommerce and web site traffic data on a smartphone, tablet, laptop or PC. The Newtek Advantage™ provides the intelligence that businesses require and will give them the advantage to succeed.  This revolutionary platform will allow owners and operators of small- and medium-sized businesses to manage their businesses from their mobile device anywhere, anytime, all without an IT department.

The Small Business Authority^® is a registered trademark of Newtek Business Services, Inc., and neither are a part of or endorsed by the U.S. Small Business Administration.

Note Regarding Forward-Looking Statements

Statements in this press release including statements regarding Newtek’s beliefs, expectations, intentions or strategies for the future, may be “forward-looking statements” under the Private Securities Litigation Reform Act of 1995.  All forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from the plans, intentions and expectations reflected in or suggested by the forward-looking statements. Such risks and uncertainties include, among others, intensified competition, operating problems and their impact on revenues and profit margins, anticipated future business strategies and financial performance, anticipated future number of customers, business prospects, legislative developments and similar matters.  Risk factors, cautionary statements and other conditions which could cause Newtek’s actual results to differ from management’s current expectations are contained in Newtek’s filings with the Securities and Exchange Commission and available through http://www.sec.gov.

For more information, please visit www.thesba.com.

Contact:

Newtek Business Services, Inc.
Barry Sloane
Chairman and CEO
212-356-9500
bsloane@thesba.com

Rubenstein Public Relations
Telephone: (212) 843-9335
Contact: Jonathan Goldberg / jgoldberg@rubensteinpr.com

Investor Relations
Telephone: (212) 273-8179
Contact: Jayne Cavuoto / jcavuoto@thesba.com

Telephone: (646) 536-7331
Contact: Brett Mass / brett@haydenir.com

(CXM) Reports On New Excellagen-Based Stromal Cell Research For Wound Healing

SAN DIEGO, Calif., Aug. 6, 2013 /PRNewswire/ — Cardium Therapeutics (NYSE MKT: CXM) today announced that it has entered into an agreement with Orbsen Therapeutics Ltd and the National University of Ireland, Galway, to utilize Cardium’s Excellagen^® pharmaceutically-formulated gel as a delivery agent for Orbsen’s proprietary stromal cell therapy in pre-clinical studies for the potential treatment of diabetic foot ulcers. The research is being conducted by the Regenerative Medicine Institute (REMEDI), at the National University of Ireland Galway (NUIG), a world-class biomedical research centre focused on mesenchymal stromal cell (MSC) research. The research initiative is funded by REDDSTAR, a European Union Framework 7 (EU FP7) research collaboration focused on treating diabetes and its complications with a defined MSC therapy and enlisting academic and industry partners throughout Europe in the program (www.reddstar.eu).

Cardium’s FDA-cleared Excellagen is an aseptically-manufactured, quaternary fibrillar Type I bovine collagen homogenate that is configured into a staggered array of three-dimensional, triple helical, telopeptide-deleted, tropocollagen molecules.  This linear array forms a flowable, biocompatible and bioactive structural matrix that promotes chemotaxis, cellular adhesion, migration and proliferation to stimulate tissue formation. The Excellagen homogenate represents a new product delivery platform that allows for the potential development of a portfolio of advanced tissue regeneration therapeutic opportunities that could include anti-infectives, antibiotics, peptides, proteins, small molecules, DNA, stem cells, differentiated cells and conditioned cell media.

About Excellagen

Excellagen is a syringe-based, professional-use, pharmaceutically-formulated 2.6% fibrillar Type I bovine collagen homogenate that functions as an acellular biological modulator to activate the wound healing process and significantly accelerate the growth of granulation tissue.  Excellagen’s FDA clearance provides for very broad labeling including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/graft, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds. Excellagen is intended for professional use following standard debridement procedures in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors.  Excellagen’s unique fibrillar Type I bovine collagen homogenate formulation is topically applied through easy-to-control, pre-filled, sterile, single-use syringes and is designed for application at only one-week intervals.

There have been important, positive findings reported by physicians using Excellagen as part of Cardium’s physician sampling, patient outreach and market “seeding” programs.  In several case studies, physicians reported a rapid onset of the growth of granulation tissue in a wide array of wounds, including non-healing diabetic foot ulcers (consistent with the results of Cardium’s Matrix clinical study), as well as pressure ulcers, venous ulcers and Mohs surgical wounds.  In certain cases, rapid granulation tissue growth and wound closure have been achieved with Excellagen following unsuccessful treatment with other advanced wound care approaches. From a dermatology perspective, a previously unexplored vertical market, remarkable healing responses have been observed following Mohs surgery for patients diagnosed with squamous and basal cell carcinomas, including deep surgical wounds extending to the periosteum (a membrane that lines the outer surface of bones).  Additionally, because of the easy-use and platelet activating capacity, physicians have been employing Excellagen in severe non-healing wounds at near-amputation status, in combination with autologous platelet-rich plasma therapy and collagen sheet products.  These case studies and positive physician feedback provide additional support of Excellagen’s potential utility as an important new tool to help promote the wound healing process. Excellagen case studies are available at http://www.excellagen.com/surgical-wounds.html.

About Orbsen Therapeutics

Orbsen Therapeutics Ltd. is a privately-held company founded in 2006 as a spin out from Ireland’s Regenerative Medicine Institute (REMEDI) in NUI Galway. As part of the PurStem EU FP7 program, Orbsen developed proprietary technologies (ORB1) that enable the prospective purification of highly defined and therapeutic stromal cells from several human tissues, including marrow, adipose tissue and umbilical cord. ORB1 stromal cells can be purified from several species including equine and murine tissues, enabling the development of defined equine MSC therapies for the first time. These novel aspects of the ORB1 technology place Orbsen at the leading edge of research, development and regulatory compliance of MSC therapies. The therapeutic ORB1 cells can be purified from a single human donor, expanded and frozen to generate many doses of high-margin, allogeneic (“off-the-shelf”) therapeutic products for indications with unmet need. Orbsen’s proprietary ORB1 MSC therapy is being developed for several indications, including inflammatory disease of the lungs and liver, diabetes, cardiovascular disorders, joint disease, kidney injury, tissue graft rejection and wound repair. For more information, please visit http://www.orbsentherapeutics.com/.

About The Regenerative Medicine Institute at NUI, Galway

The Regenerative Medicine Institute (REMEDI) is a world-class biomedical research centre focusing on gene therapy and stem cell research.  REMEDI is a partnership involving scientists, clinicians, and engineers in academic centres and in industry. Researchers at REMEDI work together to combine the technologies of gene therapy and adult stem cell therapy with the aim of regeneration and repair of tissues. The unique feature of the research carried out at REMEDI is the novel integration of both therapies in a complementary research and development programme.  Based in the National University of Ireland, Galway, REMEDI was established in 2003 through a Science Foundation Ireland (SFI) Centre for Science Engineering and Technology (CSET) award, and industry funding.  The institute is located at the National Centre for Biomedical Engineering Science and incorporates the National Cell and Gene Vector Laboratory, a GMP grade vector and cell production facility.  More information is available at http://www.nuigalway.ie/remedi/about-us.

About Cardium

Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium’s current portfolio includes LifeAgain medical data analytics, Tissue Repair Company, Cardium Biologics, and the Company’s To Go Brands^® nutraceutical business. The Company’s lead commercial product, Excellagen^® topical gel for wound care management, has received FDA clearance for marketing and sale in the United States.  Cardium’s lead clinical development product candidate Generx^® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. To Go Brands^® develops, markets and sells dietary supplements through established regional and national retailers.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. For more information, visit www.cardiumthx.com.

Forward-Looking Statements 

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations.  For example, there can be no assurance that Excellagen can be effectively applied to a stromal stem cell formulation as a regenerative medicine therapeutic for the potential treatment of diabetic foot ulcers or that it can be successfully developed for this or any other therapeutic application; that case study observations will be reproducible or generalizable, or that results or trends observed in a clinical study or follow-on case studies will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2013 Cardium Therapeutics, Inc.  All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics^®, Generx^®,Cardionovo^®, Tissue Repair™, Excellagen^®, Excellarate™, LifeAgain™, Genedexa™, Neo-Apps^®, MedPodium^®, Neo-Energy^®, Neo-Chill™ and Neo-Carb Bloc^® are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.  To Go Brands^®,  High Octane^®, Green Tea Energy Fusion™, Acai Natural Energy Boost™, Greens to Go^®, Extreme Berries to Go^®, Healthy Belly^®, VitaRocks^®, Smoothie Complete^®, Trim Green Coffee Bean™, and Trim Energy^®, are trademarks of To Go Brands, Inc.  Other trademarks belong to their respective owners.

(CNDO) Reports Financial Results for the Second Quarter

BURLINGTON, Mass., Aug. 5, 2013 (GLOBE NEWSWIRE) — Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today its financial results for the second quarter ended June 30, 2013.

“We have completed enrollment of 250 patients in our Phase 2 TRUST-I trial and remain on track to report top-line data in the fourth quarter of 2013,” said Dr. Harlan F. Weisman, Coronado’s Chairman and CEO. “The results of the TRUST-I trial will provide an abundance of data on TSO (Trichuris suis ova or CNDO-201) and the Hygiene Hypothesis, which we look forward to sharing with the medical and investment communities. A positive outcome would bring TSO one step closer to becoming an important treatment option for patients suffering from Crohn’s disease.”

“We have also further strengthened our financial position during this quarter,” continued Dr. Weisman. “From April 1, 2013 through August 2, 2013, we sold an aggregate of approximately 5.5 million shares of our common stock through our at-the-market sales facilities for net proceeds of approximately $49.4 million, including 2.2 million shares of our common stock for net proceeds of approximately $18.4 million since June 30, 2013.”

Financial Highlights:

• Coronado reported a net loss of $10.7 million and $19.5 million for the three and six months ended June 30, 2013, respectively, compared to a net loss of $6.5 million and $13.0 million for the three and six months ended June 30, 2012, respectively.
• Research and development expenses were $7.8 million and $13.8 million for the three and six months ended June 30, 2013, respectively, compared to $4.5 million and $9.1 million for the three and six months ended June 30, 2012, respectively. The increases in research and development expenses relate primarily to the TSO development program.
• General and administrative expenses were $2.5 million and $5.0 million for the three and six months ended June 30, 2013, respectively, compared to $1.9 million and $3.9 million for the three and six months ended June 30, 2012, respectively. The increases in general and administrative expenses included expenses primarily related to Coronado’s infrastructure growth to support increased business activity.
• At June 30, 2013, Coronado’s cash and cash equivalents totaled $67.9 million. To date, Coronado has sold approximately 7.1 million shares under its at-the-market sales facilities for net proceeds of approximately $61.2 million.

Other Corporate Highlights:

• Appointed Dr. George Avgerinos as Senior Vice President, Biologics Operations. Dr. Avgerinos leads Coronado’s global manufacturing and supply chain efforts for both TSO and CNDO-109. Most recently, Dr. Avgerinos was at AbbVie, formerly Abbott Laboratories, where he was Vice President, HUMIRA® Manufacturing Sciences and External Partnerships.
• Appointed Dr. Karin Hehenberger as Executive Vice President of Scientific Affairs as of August 2013. Dr. Hehenberger previously served as our Executive Vice President & Chief Medical Officer from April 2012 through July 2013. Dr. Hehenberger leads Coronado’s strategic efforts in developing novel indications for its products and serves as Coronado’s scientific communications spokesperson.

Upcoming Events:

• Wedbush 2013 Life Sciences Management Access Conference, August 13, 2013
• Canaccord Genuity 33^rd Annual Growth Conference, August 14, 2013

Conference Call and Webcast Information

Coronado management will review its second quarter financial results and development programs via conference call and webcast today at 8:30 AM ET. To participate in the conference call, please dial (877) 312-5413 (toll free from the US and Canada), or (253) 237-1511 (for international callers). Investors may also access a live audio webcast of the call at www.coronadobiosciences.com on the Events & Webcasts page.

A replay of the webcast will be available shortly after the conclusion of the call. The webcast archive will remain available for one year. An audio replay will also be available shortly after the conclusion of the call and will be made available until August 12, 2013. The audio replay can be accessed by dialing (855) 859-2056 (toll free from the US and Canada), or (404) 537-3406 (for international callers) and entering Event ID 22772111.

About Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company’s two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, including Crohn’s disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML), multiple myeloma and solid tumors. For more information, please visit www.coronadobiosciences.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the company’s product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: our ability to attract, integrate and retain key personnel; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; our dependence on third party suppliers; and competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

CONTACT: Lucy Lu, MD, Executive Vice President
         & Chief Financial Officer
         Coronado Biosciences, Inc.
         781-652-4525; ir@coronadobio.com

         Marcy Nanus, Vice President
         The Trout Group, LLC.
         646-378-2927; mnanus@troutgroup.com

         Susan Forman
         Dian Griesel Inc.
         212-825-3210; susan@dgicomm.com

(SPEX) Bounce Ahead of Merger as North South sues T-Mobile for Geolocation

NEW YORK, Aug. 5, 2013 /PRNewswire/ — North South Holdings Inc. (“North South”) — an intellectual property development company, today is announcing that one of its wholly owned subsidiaries, Guidance IP LLC, filed a complaint against T-Mobile USA, Inc. for patent infringement.

The complaint is filed in the U.S. District Court for the Middle District of Florida, the residential jurisdiction for the corporate headquarters of Harris Corporation, the original patent owner.  This lawsuit claims infringement by T-Mobile of United States Patent No. 5,719,584 entitled “System and Method for Determining the Geolocation of a Transmitter” (“‘584 Patent”).  The technology relates to the geolocation of cells phones on the T-Mobile cell phone network.  The original owner of patent ‘584 was the Harris Corporation.  North South purchased this patent along with over 200 others from Harris in 2012.    According to public filings, T-Mobile provides service to approximately 34.0 million customers through its network.

Anthony Hayes, North South CEO, stated, “This is the first complaint filed on the patents North South acquired from Harris Corporation, but we anticipate more.  This is a valuable portfolio and we will continue to demonstrate its worth as we move towards our merger with Spherix Incorporated. (NASDAQ: SPEX).  Use of North South’s intellectual property without a license is unjust and we are committed to protecting the rights afforded North South under the United States Constitution.”

About North South Holdings Inc.
North South Holdings Inc. was formed on November 9, 2012 to seek business opportunities in which to acquire patents from various entities and monetize those patents through sales, litigation or licensing.  North South recently entered into an agreement to be acquired by Spherix Incorporated (NASDAQ: SPEX).

About Spherix Incorporated
Spherix Incorporated (NASDAQ: SPEX) was launched in 1967 as a scientific research company. Spherix presently offers a diversified commercialization platform for protected technologies. The company continues to work on life sciences and drug development and presently is exploring opportunities in nutritional supplement products relying on its D-Tagatose natural sweetener as a GRAS ingredient. Spherix is committed to advancing innovation by active participation in all areas of the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation. Through its recently announced acquisition of several hundred patents issued to Harris Corporation Spherix intends to expand its activities in wireless communications and telecommunication sectors including antenna technology, Wi-Fi, base station functionality, and cellular.

Forward Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While North South believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties. Thus, actual results could be materially different. North South expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact Information:
Anthony Hayes, CEO
North South Holdings Inc.
110 Greene Street; Suite 403
New York, NY 10012
347-855-6146
anthony@northsouthholdings.com
www.northsouthholdings.com

(CXM) Announces New Excellagen FDA 510[k] Submission

The Company Also Provides Update on CE Mark Submission

SAN DIEGO, Aug. 5, 2013 /PRNewswire/ — Cardium Therapeutics (NYSE MKT: CXM) today announced that it has filed a new 510(k) submission for its current FDA-cleared Excellagen^® advanced wound care product to reflect additional and specific structural and functional properties of Excellagen based on the Company’s supplemental research and development activities.

The new 510(k) submission further characterizes Excellagen as a dermal wound matrix with structural and functional properties that play essential roles in wound healing.  Excellagen is a physiologically formulated homogenate of bovine dermal Type I collagen in its native, 3-dimensional fibrillar structural configuration that provides a scaffold for cellular infiltration and wound granulation, and which activates blood platelets that can trigger the release of essential growth factors.  The submission is supported by in vitro research findings including electron microscopy data that should allow for more specific labeling to include the unique structural and biological properties of Excellagen and its utilization to potentially enhance platelet activation when used in concert with Platelet Rich Plasma (PRP) therapy.  In addition, the Company plans to modify Excellagen’s packaging to include individually pouched applicator syringes and a large volume syringe applicator to allow for easier use in larger-sized wounds such as those found in limb salvage, orthopedic surgery and other surgical applications.

“We believe the research data provided to the FDA in our recent 510(k) submission provide further insight into the significantly accelerated and activated healing response seen with our Excellagen advanced wound care product,” stated Christopher J. Reinhard, Chairman and CEO of Cardium.  “Excellagen has multiple attributes that are beneficial to the promotion of wound healing, including activation of human platelets and the release of platelet-derived growth factor (PDGF). These findings are consistent with the role of platelet activation and the release of growth factors for one to two days following application of Excellagen to newly-debrided wounds.”

Regarding the Company’s CE mark submission, in first quarter 2013, Cardium received ISO 13485:2003 certification (a requirement for CE marking) for Excellagen by BSI, one of the world’s leading certification bodies.  With the successful completion of ISO certification, the Company reported that it had completed its initial submission of required documentation, including the technical file and design dossier for its CE mark application.  The CE mark process involves interaction between the Company and its notified body, BSI.  Since the initial submission, Cardium has received  requests for supplemental information from BSI.  Based on the current status, all information requested has been provided to BSI and the Company believes this process should lead to CE mark certification for its FDA-cleared advanced wound care product.

About Excellagen

Excellagen is a syringe-based, professional-use, pharmaceutically-formulated 2.6% fibrillar Type I bovine collagen homogenate that functions as an acellular biological modulator to activate the wound healing process and significantly accelerate the growth of granulation tissue.  Excellagen’s FDA clearance provides for very broad labeling including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/graft, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds.  Excellagen is intended for professional use following standard debridement procedures in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors.  Excellagen’s unique fibrillar Type I bovine collagen homogenate formulation is topically applied through easy-to-control, pre-filled, sterile, single-use syringes and is designed for application at only one-week intervals.

There have been important, positive findings reported by physicians using Excellagen.  In several case studies, physicians reported a rapid onset of the growth of granulation tissue in a wide array of wounds, including non-healing diabetic foot ulcers (consistent with the results of Cardium’s Matrix clinical study), as well as pressure ulcers, venous ulcers and Mohs surgical wounds.  In certain cases, rapid granulation tissue growth and wound closure have been achieved with Excellagen following unsuccessful treatment with other advanced wound care approaches.  From a dermatology perspective, a previously unexplored vertical market, remarkable healing responses have been observed following Mohs surgery for patients diagnosed with squamous and basal cell carcinomas, including deep surgical wounds extending to the periosteum (a membrane that lines the outer surface of bones).  Additionally, because of the easy-use and platelet activating capacity, physicians have been employing Excellagen in severe non-healing wounds at near-amputation status, in combination with autologous platelet-rich plasma therapy and collagen sheet products.  These case studies and positive physician feedback provide additional support of Excellagen’s potential utility as an important new tool to help promote the wound healing process.  Excellagen case studies are available at http://www.excellagen.com/surgical-wounds.html.

About Cardium

Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium’s current portfolio includes LifeAgain medical data analytics, Tissue Repair Company, Cardium Biologics, and the Company’s To Go Brands^® nutraceutical business. The Company’s lead commercial product, Excellagen^® topical gel for wound care management, has received FDA clearance for marketing and sale in the United States.  Cardium’s lead clinical development product candidate Generx^® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. To Go Brands^® develops, markets and sells dietary supplements through established regional and national retailers.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. For more information, visit www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations.  For example, there can be no assurance that we will receive a marketing clearance from the FDA for the new submission; that we can obtain a CE mark for the sale of Excellagen in the European Union and other countries recognizing CE Mark approval; that results or trends observed in a clinical study or follow-on case studies will be reproduced in subsequent studies or in actual use; that Excellagen will perform as anticipated and will be favorably received in the marketplace; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2013 Cardium Therapeutics, Inc.  All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

(DCIN) Forges Alternative Content Distro Alliance with Screenvision

Digital Cinema Destinations Corp. (NasdaqCM: DCIN) (Digiplex), a fast-growing motion picture exhibitor dedicated to transforming movie theaters into digital entertainment centers, today unveiled a new alternative content distribution alliance with national cinema advertising leader, Screenvision, effective immediately. The first planned joint theatrical title will be the hard-hitting documentary ‘The United States of Football’ (The USOF), which debuts August 23 in a limited, exclusive release at Digiplex theaters and also at select locations in major cities, including New York, Los Angeles and Chicago. A complete list of theaters, ticketing and show-times will be available later in August at www.THEUSOF.com. Starting August 30, The USOF will expand the engagement on a wider national platform in theaters that are members of Screenvision’s 14,000+ screen footprint across the US.

“Digiplex has positioned itself on the cutting-edge of theatrical exhibition innovation,” stated Screenvision CEO Travis Reid, “and we are very pleased to commence what we believe will be an exciting and mutually beneficial relationship with their team. In addition to distributing curated content from their DigiNext JV, we will also be booking a variety of other entertainment sourced from Digiplex throughout our domestic exhibitor network.”

Bud Mayo, Chairman and CEO of Digiplex, added, “Joining forces with cinema advertising leader Screenvision is a clear win-win for both organizations, and importantly, this will result in a much larger release platform for unique, specialty content that deserves a much wider audience. Importantly, this alliance is expected to generate additional, accretive new revenue streams for us, including downstream and ancillary digital downloads. We are delighted to hit the ground running with the first release from DigiNext’s second season, ‘The United States of Football.’”

The USOF explores the cumulative effects of repetitive trauma in America’s Game, from Pee-Wees to the pros. Fans and parents of young players follow a father’s quest for an answer to, “Should my kid play?” From ‘Bountygate’ to the challenges faced in youth leagues by shortfalls in knowledge or funding, Emmy-winning filmmaker Sean Pamphilon takes a tough look at what will be needed in order to save the players as well as the sport we love. The movie features, among others, Bob Costas, Mike Ditka, Kyle Turley, Jim Brown, Chris Henry, Malcolm Gladwell and James Harrison.

About Digital Cinema Destinations Corp. (www.digiplexdest.com)

Digital Cinema Destinations Corp. (NasdaqCM: DCIN) is Digiplex Destinations, dedicated to transforming its movie theaters into interactive entertainment centers. The Company provides consumers with uniquely satisfying experiences, combining state-of-the-art digital technology with engaging, dynamic content that far transcends traditional cinematic fare. The Company’s customers enjoy live opera, ballet, Broadway shows, sports events, concerts and, on an ongoing basis, the very best major motion pictures. Digiplex operates 19 cinemas and 184 digital screens in AZ, CA, CT, OH, PA and NJ. You can connect with Digiplex via Facebook, Twitter, YouTube and Blogger. Digiplex is also a partner in DigiNext, a unique, specialty content joint venture (with Nehst) featuring curated content from festivals around the world. DigiNext releases typically include innovative live Q&A sessions between the audience and cast members.

ABOUT SCREENVISION

Headquartered in New York, N.Y., Screenvision is a national leader in cinema advertising, offering on-screen advertising, in-lobby promotions and integrated marketing programs to national, regional and local advertisers and providing comprehensive cinema advertising representation services to top tier theatrical exhibitors presenting the highest quality moviegoing experience. The Screenvision cinema advertising network is comprised of over 14,200 screens in 2,200+ theater locations across all 50 states and 94% of DMAs nationwide; delivering through more than 150 theatrical circuits, including 6 of the top 10 exhibitor companies. For more information: http://www.screenvision.com.

(TTHI) Enters Into a Private Placement with Investors for up to $21.7M

Company to Receive Upfront US$11 Million Upon Closing

TORONTO, Aug. 2, 2013 /PRNewswire/ – Transition Therapeutics Inc. (“Transition” or the “Company”) (NASDAQ: TTHI, TSX: TTH) announced that Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders will make an investment of up to US$21 million by purchasing 2,625,298 units of the Company at a price of US$4.19 per common share.

Each unit consists of (i) one common share, (ii) 0.325 Common Share purchase warrant with a purchase price of US$4.60 per whole warrant and (iii) 0.4 Common Share purchase warrant with a purchase price of US$6.50 per whole warrant.   Each whole warrant will entitle the holder, within two years from closing, to purchase one additional common share in the capital of the Company.  If and when all of the warrants are exercised, the Company will realize an additional US$10.7 million, bringing the total investment to US$21.7 million before transaction costs.  Closing of the private placement is expected to occur on or about August 15, 2013 and is subject to approval from the Toronto Stock Exchange.

“This offering provides sufficient funding for the Company through the completion of three major Phase 2 studies, each of which could transform the value of the Company.   In parallel, this offering will allow the Company to continue its business strategy of in-licensing and developing a strong pipeline of molecules through partnerships with pharmaceutical companies. I am very pleased with the on-going commitment and support of our large investors, Board and management that contributed to the financing of the offering,” said Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition.

These securities have not been registered under the U.S. Securities Act of 1933, as amended (the “Act”), and may not be offered or sold in the United States unless registered under the Act or unless an exemption from registration is available. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Transition

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. The Company’s lead CNS drug candidate is ELND005 for the treatment of Alzheimer’s disease and bipolar disorder.  Transition’s lead metabolic drug candidate is TT-401 for the treatment of type 2 diabetes and accompanying obesity. The Company’s shares are listed on the NASDAQ under the symbol “TTHI” and the Toronto Stock Exchange under the symbol “TTH”. For additional information about the Company, please visit www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the Canadian Securities Commissions, the U.S. Securities and Exchange Commission or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including the total aggregate investment to be made in the Company, the conduct of clinical trials and the potential efficacy of its products. These statements are based upon the current expectations and beliefs of Transition’s management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition’s control and the risk factors and other cautionary statements discussed in Transition’s quarterly and annual filings with the Canadian Securities Commissions and the U.S. Securities and Exchange Commission.

(CPRX) Regains Compliance With NASDAQ Minimum Bid Price Rule

CORAL GABLES, Fla., Aug. 2, 2013 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, announced today that it has received notice from the NASDAQ Stock Market (“NASDAQ”) on August 2, 2013 confirming that the Company has regained compliance with the $1.00 per share minimum bid price requirement for continued listing on the NASDAQ Capital Market.

As previously announced, on December 24, 2012, NASDAQ notified the Company that the bid price of its common stock had closed at less than $1.00 per share over the previous 30 consecutive trading days and, as a result, the Company was not in compliance with Listing Rule 5550(a)(2)(“Rule”), the minimum bid price rule. The Company was provided 180 calendar days, or until June 24, 2013 to regain compliance with the Rule. Additionally, on June 25, 2013, NASDAQ notified the Company that it had been granted an additional 180-day extension period, or until December 23, 2013, in which to regain compliance with the Rule.

On August 2, 2013, NASDAQ notified the Company that the closing bid price of its common stock has been at $1.00 per share or greater at least 10 consecutive trading days. Accordingly, NASDAQ has confirmed to the Company that it has regained compliance with the minimum bid price rule and the matter is now closed.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette Syndrome. Catalyst’s lead candidate, Firdapse™ for the treatment of LEMS, is currently undergoing testing in a global, multi-center, pivotal phase III trial. Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115) to treat infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder, Tourette Syndrome, and movement disorders.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including whether Catalyst will continue to remain in compliance with the Nasdaq listing standards, as well as those factors described in Catalyst’s Annual Report on Form 10-K for the fiscal year 2012 and other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CONTACT: For Further Information Contact:
         Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com

         Melody Carey
         Rx Communications Group
         Co-President
         (917) 322-2571
         mcarey@rxir.com

(CTHR) Gains Distribution for Moissanite on Amazon

Represents the company’s first sales partnership with Amazon and design collaboration with Charles Winston

Charles & Colvard, Ltd. (NASDAQ:CTHR), the exclusive global supplier of the moissanite gem, entered into a distribution agreement with Amazon.com, the world’s largest e-commerce marketplace, to directly supply moissanite fine jewelry to the online retailer starting August 2013.

“Amazon’s commitment to superior customer service coupled with its state-of-the-art jewelry shopping section offers an ideal platform to increase awareness of the value and luxury of moissanite jewelry,” said Randy N. McCullough, CEO at Charles & Colvard. “Our more brilliant, ethical and cost-effective alternative to diamonds paired with Amazon’s e-commerce expertise creates an exciting partnership. We’re looking forward to continued growth and future success.”

The partnership between Charles & Colvard and Amazon.com will increase national and international consumer access to moissanite, the most world’s most brilliant gem™, through the Charles W. Moissanite Signature Collection designed by Charles Winston. “This partnership with the world’s largest e-tailer,” continued McCullough, “further expands our distribution network and exemplifies the consumer acceptance and excitement for our proprietary moissanite gemstone.”

The Charles W. Moissanite Signature Collection on Amazon has launched with a showing of essential, classic fashion jewelry pieces all designed in 14 karat gold in collaboration with Charles Winston, continuing five generations of family tradition in fine jewelry design. The collection is available through Amazon’s recently remodeled jewelry section. Additional design offerings including set in fine silver are planned for the fall of 2013 and Valentines’ Day 2014.

More information about the entire Charles & Colvard moissanite line is available at http://www.charlesandcolvard.com/.

About Charles & Colvard:

Charles & Colvard, Ltd., based in the Research Triangle Park area of North Carolina, is the global sole source of moissanite, a unique, near-colorless created gemstone that is distinct from other gemstones and jewels based on its exceptional fire, brilliance, luster, durability, and rarity. Charles & Colvard Created Moissanite^® and Forever Brilliant^® are currently incorporated into fine jewelry sold through domestic and international retailers and other sales channels. Charles & Colvard, Ltd.’s common stock is listed on the NASDAQ Global Select Market under the symbol “CTHR.” For more information, please visit www.charlesandcolvard.com.

(EGOV) Receives International Award for Outstanding Achievement

Interactive Media Awards (IMA) recently announced the winners for the First Quarter 2013 competition recognizing outstanding achievement in the design, development, management and promotion of websites to increase the standards of excellence on the Internet. The LiensNC site, https://apps.liensnc.com, received an Outstanding Achievement Award, specifically honored for excellence in the Reference category.

The Outstanding Achievement Award is presented to entries that excel in various criteria including design, usability, innovation in technical features, standards compliance and content. In order to win this award, the site had to meet strict guidelines in each area — achieved by only a fraction of IMA entries.

Executive Board President of LiensNC, LLC, Nancy Ferguson, said, “LiensNC LLC, was fortunate to partner with NIC‘s exceptional leadership, technical and creative teams for implementation of this landmark legislation, even as it was an ongoing work in progress. NIC created the web application platform in a phenomenally short time frame while maintaining high quality standards.”

The LiensNC template features a responsive design that allows the site to be viewed from a variety of display sizes without losing important details or features. LiensNC utilizes a QR code feature, which was designed to give potential lien claimants an easily accessible method for using the site from their mobile device while on location at the construction project site. In addition to incorporating new technologies, the site uses clean lines, simplistic content, and an easy flow in an effort to increase the usability of the system.

“We are extremely honored to receive recognition for Outstanding Achievement through such a prestigious award,” said Mukesh Patel, NIC Services, LLC President. “It was a challenge to create a system that met the specific statutory requirements while keeping focus of the varied uses and demands of owners, contractors, potential lien claimants and closing attorneys. My team spent countless hours planning, developing, designing, and implementing the LiensNC website, and we are committed to continue improving this service in North Carolina.”

About LiensNC, LLC

LiensNC, LLC is a joint venture of the nine title insurance underwriters who provide most of the title insurance coverage in North Carolina. The mission statement of the LLC: “Working to protect mechanics’ lien rights and provide transparency of information related to real property law through quality and professional services.”

About NIC

NIC Inc. (NASDAQ: EGOV) is the nation’s leading provider of official government portals, online services, and secure payment processing solutions. The company’s innovative eGovernment services help reduce costs and increase efficiencies for government agencies, citizens, and businesses across the country. NIC provides eGovernment solutions for more than 3,500 federal, state, and local agencies in the United States. Additional information is available at http://www.egov.com.

About NIC Services, LLC

NIC Services is a wholly owned subsidiary of NIC and provides consolidated payment services. This experience has allowed NIC to develop a system of operational best practices that encompass the full lifecycle of payments, from origination to disbursement to reporting. These practices allow NIC to deliver secure, reliable, and enterprise payment solutions to our partners.

(GALE) to Present at the 8th Annual JMP Securities Healthcare Conference

LAKE OSWEGO, Ore., July 2, 2013 (GLOBE NEWSWIRE) — Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President & CEO, will present a corporate update at the 8^th Annual JMP Securities Healthcare Conference. The presentation will take place on Wednesday, July 10, 2013 at 10:30 a.m. ET at The St. Regis Hotel in New York, NY.

The presentation will be webcast and available on the Investors section of the Company’s website at www.galenabiopharma.com.

About Galena Biopharma

Galena Biopharma, Inc. (Nasdaq:GALE) is a Portland, Oregon-based biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. For more information please visit us at www.galenabiopharma.com.

CONTACT: Remy Bernarda
         Senior Director, Communications
         (503) 405-8258
         rbernarda@galenabiopharma.com

(PRFT) Reports Second Quarter 2013 Results

Perficient, Inc. (NASDAQ: PRFT) (“Perficient”), a leading information technology consulting firm serving Global 2000® and other large enterprise customers throughout North America, today reported its financial results for the quarter ended June 30, 2013.

Financial Highlights

For the quarter ended June 30, 2013:

• Revenues increased 15% to $94.2 million from $81.8 million for the second quarter 2012;
• Services revenue increased 11% to $80.4 million from $72.7 million for the second quarter 2012;
• Adjusted earnings per share results (a non-GAAP measure; see attached schedule, which reconciles to GAAP earnings per share) on a fully diluted basis increased to $0.28 from $0.24 for the second quarter 2012;
• Earnings per share results on a fully diluted basis increased to $0.14 from $0.12 for the second quarter 2012;
• EBITDAS (a non-GAAP measure; see attached schedule, which reconciles to GAAP net income) increased to $14.5 million from $12.5 million for the second quarter 2012;
• Net income increased 27% to $4.6 million compared to $3.6 million for the second quarter 2012; and
• Repurchased 775,000 shares of its common stock at a cost of $9.5 million.

“Perficient is executing well on key performance metrics as we head into the second half of 2013,” said Jeffrey Davis, chief executive officer and president. “The world’s leading enterprises are increasingly recognizing our unique capacity to deliver a wide array of business-driven technology solutions by combining industry expertise with deep technical skills across multiple platforms.”

“Average bill rates reached an all-time high in the second quarter,” said Paul Martin, chief financial officer. “Opportunity remains to continue to gradually improve rates and manage utilization to drive services margins higher and realize increasing profitability.”

Other Highlights

Among other recent achievements, Perficient:

• Was named Microsoft’s 2013 US Partner of the Year, taking top honor among all partners in the United States for demonstrating excellence in innovation and implementation of Microsoft technologies. In addition, Perficient was selected as Microsoft’s Healthcare Provider Partner of the Year, Microsoft’s Central Region Cloud Partner of the Year, East Region NSI Partner of the Year and the Northeast District Cloud Partner of the Year.
• Completed two acquisitions in the month of May, which broadened Perficient’s portfolio and expanded the company’s presence in key markets. Most recently, Perficient acquired San Francisco-based Clear Task, Inc., an $8 million annual services revenue consulting firm focused entirely on the salesforce.com product suite. Perficient also acquired TriTek Solutions, Inc., a $19 million annual IBM- focused enterprise content management and business process management consulting firm.

• Expanded its share repurchase program increasing the total authorization to $90 million from the previous total of $70 million. The stock repurchase program runs through Dec. 31, 2014;
• Increased the size of its credit facility from $50m to $75m, reducing interest rates and extending the term to July 2017;
• Added new customer relationships and follow-up projects with leading companies including: Canon USA, Carters, CDW, CH2M Hill, Marathon Oil, Stryker, Texas Children’s Health Plan, Vitamin Shoppe and WireCo WorldGroup; and
• Was named a Top Workplace by both the St. Louis Post-Dispatch and Minneapolis Star Tribune. Perficient was honored for its entrepreneurial spirit, expertise with cutting-edge technologies, and strong reputation in the technology consulting industry.

Business Outlook

The following statements are based on current expectations. These statements are forward-looking and actual results may differ materially. See “Safe Harbor Statement” below.

Perficient expects its third quarter 2013 services and software revenue, including reimbursed expenses, to be in the range of $91.8 million to $98.3 million, comprised of $86.8 million to $91.3 million of revenue from services including reimbursed expenses and $5.0 million to $7.0 million of revenue from sales of software. The midpoint of third quarter 2013 services revenue guidance represents growth of 12% over third quarter 2012 services revenue.

The company is reaffirming its full year 2013 revenue guidance range of $362 million to $382 million and raising 2013 Adjusted GAAP earnings per share guidance to a range of $1.03 to $1.09 from the previously provided range of $0.98-$1.08.

Conference Call Details

Perficient will host a conference call regarding second quarter 2013 financial results today at 10 a.m. Eastern.

WHAT: Perficient Reports Second Quarter 2013 Results
WHEN: Thursday, August 1, 2013, at 10 a.m. Eastern
CONFERENCE CALL NUMBERS: 866-318-8614 (U.S. and Canada) 617-399-5133 (International)
PARTICIPANT PASSCODE: 67126414
REPLAY TIMES: Thursday, August 1, 2013, at 12 p.m. Eastern, through Thursday, August 8, 2013
REPLAY NUMBER: 888-286-8010 (U.S. and Canada) 617-801-6888 (International)
REPLAY PASSCODE: 25656774

About Perficient

Perficient is a leading information technology consulting firm serving Global 2000 and enterprise customers throughout North America. Perficient’s professionals serve clients from a network of offices across North America and three offshore locations, in Eastern Europe, India, and China. Perficient helps clients use Internet-based technologies to improve productivity and competitiveness, strengthen relationships with customers, suppliers and partners, and reduce information technology costs. Perficient, traded on the Nasdaq Global Select Market, is a member of the Russell 2000® index and the S&P SmallCap 600 index. Perficient is an award-winning “Premier Level” IBM business partner, a Microsoft National Systems Integrator and Gold Certified Partner, an Oracle Platinum Partner, a Gold salesforce.com Cloud Alliance Partner, a TeamTIBCO partner, and an EMC Select Services Team Partner. For more information, please visit www.perficient.com.

Safe Harbor Statement

Some of the statements contained in this news release that are not purely historical statements discuss future expectations or state other forward-looking information related to financial results and business outlook for 2013. Those statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The “forward-looking” information is based on management’s current intent, belief, expectations, estimates, and projections regarding our company and our industry. You should be aware that those statements only reflect our predictions. Actual events or results may differ substantially. Important factors that could cause our actual results to be materially different from the forward-looking statements include (but are not limited to) those disclosed under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2012 and the following:

(1) the possibility that our actual results do not meet the projections and guidance contained in this news release;
(2) the impact of the general economy and economic uncertainty on our business;
(3) risks associated with the operation of our business generally, including:

a. client demand for our services and solutions;
b. maintaining a balance of our supply of skills and resources with client demand;
c. effectively competing in a highly competitive market;
d. protecting our clients’ and our data and information;
e. risks from international operations;
f. obtaining favorable pricing to reflect services provided;
g. adapting to changes in technologies and offerings; and
h. risk of loss of one or more significant software vendors;

(4) legal liabilities, including intellectual property protection and infringement;
(5) risks associated with managing growth through acquisitions and organically; and
(6) the risks detailed from time to time in our filings with the Securities and Exchange Commission.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. This cautionary statement is provided pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release are made only as of the date hereof and we undertake no obligation to update publicly any forward-looking statement for any reason, even if new information becomes available or other events occur in the future.

About Non-GAAP Financial Information

This press release includes non-GAAP financial measures. For a description of these non-GAAP financial measures, including the reasons management uses each measure, and reconciliations of these non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with Generally Accepted Accounting Principles (“GAAP”), please see the section entitled “About Non-GAAP Financial Measures” and the accompanying tables entitled “Reconciliation of GAAP to Non-GAAP Measures.”

About Non-GAAP Financial Measures

Perficient provides non-GAAP financial measures for EBITDAS (earnings before interest, income taxes, depreciation, amortization, and stock compensation), adjusted net income, and adjusted net income per share data as supplemental information regarding Perficient’s business performance. Perficient believes that these non-GAAP financial measures are useful to investors because they provide investors with a better understanding of Perficient’s past financial performance and future results. Perficient’s management uses these non-GAAP financial measures when it internally evaluates the performance of Perficient’s business and makes operating decisions, including internal operating budgeting, performance measurement, and the calculation of bonuses and discretionary compensation. Management excludes stock-based compensation related to employee stock options and restricted stock awards, the amortization of intangible assets, acquisition costs, adjustments to the fair value of contingent consideration, and income tax effects of the foregoing, when making operational decisions. Perficient believes that providing the non-GAAP financial measures to its investors is useful because it allows investors to evaluate Perficient’s performance using the same methodology and information used by Perficient’s management. Specifically, adjusted net income is used by management primarily to review business performance and determine performance-based incentive compensation for executives and other employees. Management uses EBITDAS to measure operating profitability, evaluate trends, and make strategic business decisions.

Non-GAAP financial measures are subject to inherent limitations because they do not include all of the expenses included under GAAP and because they involve the exercise of discretionary judgment as to which charges are excluded from the non-GAAP financial measure. However, Perficient’s management compensates for these limitations by providing the relevant disclosure of the items excluded in the calculation of EBITDAS, adjusted net income, and adjusted net income per share. In addition, some items that are excluded from adjusted net income and adjusted earnings per share can have a material impact on cash. Management compensates for these limitations by evaluating the non-GAAP measure together with the most directly comparable GAAP measure. Perficient has historically provided non-GAAP financial measures to the investment community as a supplement to its GAAP results to enable investors to evaluate Perficient’s business performance in the way that management does. Perficient’s definition may be different from similar non-GAAP financial measures used by other companies and/or analysts.

The non-GAAP adjustments, and the basis for excluding them, are outlined below:

Amortization of Intangible Assets

Perficient has incurred expense on amortization of intangible assets primarily related to various acquisitions. Management excludes these items for the purposes of calculating EBITDAS, adjusted net income, and adjusted net income per share. Perficient believes that eliminating this expense from its non-GAAP financial measures is useful to investors because the amortization of intangible assets can be inconsistent in amount and frequency, and is significantly impacted by the timing and magnitude of Perficient’s acquisition transactions, which also vary substantially in frequency from period to period.

Acquisition Costs

Perficient incurs transaction costs related to acquisitions which are expensed in its GAAP financial statements. Management excludes these items for the purposes of calculating EBITDAS, adjusted net income, and adjusted net income per share. Perficient believes that excluding these expenses from its non-GAAP financial measures is useful to investors because these are expenses associated with each transaction, and are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult.

Adjustments to Fair Value of Contingent Consideration

Perficient is required to remeasure its contingent consideration liability related to acquisitions each reporting period until the contingency is settled. Any changes in fair value are recognized in earnings. Management excludes these items for the purposes of calculating adjusted net income and adjusted net income per share. Perficient believes that excluding these adjustments from its non-GAAP financial measures is useful to investors because they are related to acquisitions, and are inconsistent in amount and frequency from period to period.

Stock-Based Compensation

Perficient incurs stock-based compensation expense under Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation – Stock Compensation. Perficient excludes this item for the purposes of calculating EBITDAS, adjusted net income, and adjusted net income per share because it is a non-cash expense, which Perficient believes is not reflective of its business performance. The nature of stock-based compensation expense also makes it very difficult to estimate prospectively, since the expense will vary with changes in the stock price and market conditions at the time of new grants, varying valuation methodologies, subjective assumptions, and different award types, making the comparison of current results with forward looking guidance potentially difficult for investors to interpret. The tax effects of stock-based compensation expense may also vary significantly from period to period, without any change in underlying operational performance, thereby obscuring the underlying profitability of operations relative to prior periods. Perficient believes that non-GAAP measures of profitability, which exclude stock-based compensation are widely used by analysts and investors.

(SPRT) Expands Tech Expert Workforce With National Hiring Campaign

REDWOOD CITY, Calif., Aug. 1, 2013 (GLOBE NEWSWIRE) — Support.com, Inc. (Nasdaq:SPRT), a leading provider of cloud-based technology services and software that create new revenue streams and improve customer experience, today announced that it is hiring hundreds of Remote Services Technicians, specializing on home networking support, to meet the growing demand for premium technology support services. All technicians work from home and are powered by Support.com’s patented Nexus^® Service Delivery Platform to diagnose and deliver services faster while delighting the customer.

“Support.com’s success has been driven by combining an outstanding workforce with our cloud-based technology platform. Our experience has shown that a work-from-home model, which attracts the best and brightest techs from across the country, is uniquely suited for the delivery of technology support services,” said Josh Pickus, President and CEO, Support.com. “As the demand for technology support services grows, driven by the complexity of home networks and mobile devices, we are excited to offer high quality employment opportunities for hundreds of Americans.”

Prospective Support.com Remote Services Technicians are bright, self-motivated individuals who are able to quickly learn new technical concepts and who are confident communicating technical directions to inexperienced computer users. All Remote Services Technicians receive rigorous online training in the delivery of home networking services to ensure that they meet the “best-in-class” standards of technical aptitude and customer service. Remote Services Technicians are employees who receive benefits, competitive compensation and career advancement opportunities.

Support.com offers its partners a broad array of remote and onsite premium technology support services to meet the current and future technology needs of their consumer and small business customers. Support.com also licenses the Nexus Service Delivery Platform to technology support organizations to reduce costs, improve problem resolution and enhance the customer experience.

North American residents who would like to apply can click or visit http://www.support.com/about/careers/openings to review the qualifications for employment and submit a confidential application.

About Support.com

Support.com, Inc. (Nasdaq:SPRT) is a leading provider of cloud-based technology services and software. We help leading brands create new revenue streams and deepen customer loyalty through programs that enhance their customers’ technology experience. Our solution includes a comprehensive Service Delivery Platform, mobile and desktop apps, a scalable workforce of technology specialists and proven expertise in program design and execution. Our partners include many of the nation’s leading communications providers, retailers and technology companies. For more information, please visit us at: www.support.com.

The Support.com, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11893

Support.com, Inc. is an Equal Opportunity Employer. For more information, visit http://www.support.com/about/careers.

Copyright © 2013 Support.com, Inc. All rights reserved. Support.com and Nexus are trademarks or registered trademarks of Support.com, Inc. in the United States and other countries.

CONTACT: Media Contact
         Seth Geisler
         Martin Levy Public Relations
         (858) 610-9860
         seth@martinlevypr.com

(BCRX) to Announce Second Quarter 2013 Financial Results August 8

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its second quarter 2013 financial results will be released on Thursday, August 8, 2013. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update on the Company’s programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Thomas R. Staab, II, Senior Vice President and Chief Financial Officer and Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer.

Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and inflammatory diseases, with the goal of addressing unmet medical needs of patients and physicians. BioCryst currently has two late-stage development programs: peramivir, a viral neuraminidase inhibitor for the treatment of influenza, and ulodesine, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout. In addition, BioCryst has several early-stage programs: BCX4161 and a next generation oral inhibitor of plasma kallikrein for hereditary angioedema and BCX4430, a broad spectrum antiviral for hemorrhagic fevers. For more information, please visit the Company’s website at www.BioCryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.

(LIVE) Retains Constellation Asset Advisors for IR, Strategic Market Planning

Live Deal, Inc. Retains Constellation Asset Advisors, Inc. to Assist in Investor Awareness and Precision Strategic Market Planning

(CXM) Reports On New Excellagen Distribution Agreement With AvKARE

SAN DIEGO, Aug. 1, 2013 /PRNewswire/ — Cardium Therapeutics (NYSE MKT:CXM) today announced that it has entered into a distribution agreement with AvKARE Inc. to become the new sales and distribution partner for Excellagen^® in government medical facilities throughout the United States. This new agreement and commercialization arrangement with AvKARE effectively replaces an earlier arrangement with Academy Medical, LLC.  Cardium elected to transfer the Excellagen distribution responsibilities to AvKARE, which provides five direct wound care experts and allows Cardium’s 25 distributor representatives access to all government accounts.  AvKARE services a diverse customer base that includes government (federal, state and municipal) and commercial sectors.

About AvKARE

AvKARE, a HealthKARE company, is a licensed manufacturer/wholesaler of pharmaceuticals, disposable medical supplies and capital medical equipment. The officers and management team at AvKARE have more than 80 years’ experience in the pharmaceutical and medical supply industry. AvKARE, which is known for its national distribution, services a diverse customer base that includes government (federal, state and municipal) and commercial sectors.  AvKARE serves the Department of Defense, Veterans Hospitals, NASA, TriCare, Dept. of Agriculture, Indian Health Services, USDA, U.S. Army, Air Force, Navy, and USMC, as well as Group Purchasing Organizations that include Amerinet, Innovatix, Health Trust Purchasing Group, IPC, Broadlane/MedAssets and Premier.  AvKARE also holds National Government contracts, Federal Supply Schedule, as well as multiple Blanket Purchase Agreements.  To learn more about AvKARE, visit www.Excellagen.com/AvKARE.

About Excellagen

Excellagen is a syringe-based, professional-use, pharmaceutically-formulated 2.6% fibrillar Type I bovine collagen homogenate that functions as an acellular biological modulator to activate the wound healing process and significantly accelerate the growth of granulation tissue.  Excellagen’s FDA clearance provides for very broad labeling including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/graft, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds.  Excellagen is intended for professional use following standard debridement procedures in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors.  Excellagen’s unique fibrillar Type I bovine collagen homogenate formulation is topically applied through easy-to-control, pre-filled, sterile, single-use syringes and is designed for application at only one-week intervals.

There have been important, positive findings reported by physicians using Excellagen.  In several case studies, physicians reported a rapid onset of the growth of granulation tissue in a wide array of wounds, including non-healing diabetic foot ulcers (consistent with the results of Cardium’s Matrix clinical study), as well as pressure ulcers, venous ulcers and Mohs surgical wounds.  In certain cases, rapid granulation tissue growth and wound closure have been achieved with Excellagen following unsuccessful treatment with other advanced wound care approaches.  From a dermatology perspective, a previously unexplored vertical market, remarkable healing responses have been observed following Mohs surgery for patients diagnosed with squamous and basal cell carcinomas, including deep surgical wounds extending to the periosteum (a membrane that lines the outer surface of bones).  Additionally, because of the easy-use and platelet activating capacity, physicians have been employing Excellagen in severe non-healing wounds at near-amputation status, in combination with autologous platelet-rich plasma therapy and collagen sheet products.  These case studies and positive physician feedback provide additional support of Excellagen’s potential utility as an important new tool to help promote the wound healing process.  Excellagen case studies are available at http://www.excellagen.com/surgical-wounds.html.

About Cardium

Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium’s current portfolio includes LifeAgain medical data analytics, Tissue Repair Company, Cardium Biologics, and the Company’s To Go Brands^® nutraceutical business. The Company’s lead commercial product, Excellagen^® topical gel for wound care management, has received FDA clearance for marketing and sale in the United States.  Cardium’s lead clinical development product candidate Generx^® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. To Go Brands^® develops, markets and sells dietary supplements through established regional and national retailers.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. For more information, visit www.cardiumthx.com.

Forward-Looking Statements 

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations.  For example, there can be no assurance that this or other distribution agreements will effectively expand access or lead to increased adoption by medical providers; that results or trends observed in a clinical study or follow-on case studies will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2013 Cardium Therapeutics, Inc.  All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics^®, Generx^®,Cardionovo^®, Tissue Repair™, Excellagen^®, Excellarate™, LifeAgain™, Genedexa™, Neo-Apps^®, MedPodium^®, Neo-Energy^®, Neo-Chill™ and Neo-Carb Bloc^® are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.  To Go Brands^®,  High Octane^®, Green Tea Energy Fusion™, Acai Natural Energy Boost™, Greens to Go^®, Extreme Berries to Go^®, Healthy Belly^®, VitaRocks^®, Smoothie Complete^®, Trim Green Coffee Bean™, and Trim Energy^®, are trademarks of To Go Brands, Inc.  Other trademarks belong to their respective owners.